The global hypoventilation management market is expected to reach a valuation of US$ 7.1 billion in 2023, and is projected to reach US$ 11.9 billion by 2033, trailing a CAGR of 5.3% during the forecast period.
Growing healthcare expenditure, advancement in the treatment options, unhealthy lifestyle, rising incidence of obesity, growing initiatives by government and private organisations to spread awareness towards health and lack of exercise in the daily routine are the factors that will expand hypoventilation syndrome treatment market.
Also, increase in the research and development activities and ongoing clinical trials will provide beneficial opportunities for hypoventilation syndrome treatment market in the forecast period of 2023-2033.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 7.1 billion |
| Anticipated Forecast Value (2033) | US$ 11.9 billion |
| Projected Growth Rate (2023 to 2033) | CAGR 5.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for hypoventilation management was worth US$ 6 billion in 2018, while growing at a CAGR of 3.42% during the historical period. The growth of hypoventilation drug market is being fuelled by increasing demand for medications to treat symptoms such as shortness of breath, coughing, mucus production, and wheezing, as well as the convenience and ease of using these treatments and therapies in the comfort of one's own home. A better understanding of respiratory illnesses, their treatments, and the necessary precautions has an additional effect on the market for medications used to treat hypoventilation diseases.
The value of the market for treatments for hypoventilation disease is boosted by the rising funding of research and development and drug production by governments and pharmaceutical corporations. Asthma and Chronic obstructive pulmonary diseases are on the rise, and the senior population is also on the rise, thus these are three main factors pushing the industry forward.
The global market value for Hypoventilation management is poised to increase significantly as a result of the government approving medicines and biosimilars. This market is booming thanks to improvements in healthcare infrastructure, shifting consumer preferences, and increasing disposable income. Considering the above-mentioned factors, the market of hypoventilation is expected to be worth US$ 11.9 billion with a CAGR of 5.3% by end of the forecast period.
Advancements in medical technology propelling market growth
Increasing prevalence of sleep related hypoventilation and growing healthcare expenditure are the major factors driving market growth. Furthermore, advancement in the medical technology, rising government funding and growing initiatives by public and private organisations to spread awareness about the disease and its preventive options are the factors that will expand hypoventilation treatment market.
Other factors including alcohol abuse, growing incidences of obesity, asthma and hypothyroidism and utilization of medication involving opiates and benzodiazepines will also help in propelling the market growth.
Principal Consultant
High cost of treatment restraining industry expansion
High cost of treatment and complications associated with various hypoventilation syndrome such as obesity related hypoventilation, sleep related hypoventilation, Chronic obstructive pulmonary disease, are the factors that will challenge market growth and will further restrain the hypoventilation syndrome treatment market in the forecast period.
North America expected to dominate the market with the maximum share
North America accounted for the largest share of around 41% of the global market in 2022. The market in the region is projected to grow at a CAGR of 4.39% from 2023 to 2033. This can be ascribed to the highly structured healthcare industry and the availability of well-defined reimbursement policies from private and public health insurance firms.
Furthermore, growth in research & development activities to provide advanced and efficient products, and the presence of key players are driving the hypoventilation treatment market size in this region.
The market in South-Asia expected to witness fastest CAGR
The market in South-Asia is expected to grow at the fastest CAGR of 5.5% during the forecast period. The region has a relatively untapped chronic obstructive pulmonary disease treatment market compared to developed regions.
Therefore, South Asia offers significant opportunities to market players. High prevalence of chronic obstructive pulmonary disease, increase in geriatric population, surge in patient population, and growth of the health care industry are propelling the hypoventilation treatment market in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Chronic obstructive pulmonary disease driving growth with maximum share
Chronic obstructive pulmonary disease is projected to dominate the market with a market share of around 55% by end of the forecast period. This segment is estimated to reflect a CAGR of 6% during the forecast period. Adoption of combination therapies including LAMA-ICS, LABA-ICS, triple therapy, and other combination drugs are boosting the segment’s growth. Adoption of these therapies is increasing, as it is more effective than the separate use of bronchodilators and corticosteroids.
Growth in the number of patients successfully treated with combination therapy who were not showing signs of recovery with bronchodilators or corticosteroid treatments is anticipated to fuel the growth of chronic obstructive pulmonary disease treatment. Moreover, combination therapy is more effective than monotherapy for improving symptoms and quality of life. Thus, boosting the segment’s growth.
Hospitals will lead the segment with the maximum share
This segment is expected to lead the market with a market share of 71% by end of the forecast period. Rising investments in healthcare infrastructure, easy availability of diagnostic machines, and easy access to skilled professionals are some of the factors driving the growth of this segment. Furthermore, hospitals are convenient for using combination therapies in the treatment of hypoventilation disorder which also boosts this segment’s growth.
The global Hypoventilation management market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Accord Healthcare Limited, Avet Pharmaceuticals Inc, Nostrum Laboratories Inc, Lannett Co Inc, Strides Pharma Science Limited, X Gen Pharmaceuticals Inc, ResMed, Koninklijke Philips NV, Hikma Pharmaceuticals, Lincare Holdings
Some recent developments in this industry are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 7.1 billion |
| Market Value in 2033 | US$ 11.9 billion |
| Growth Rate | CAGR of 5.3% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global Hypoventilation management market to expand at a 5.3% value CAGR by 2033.
The global Hypoventilation management market is expected to garner a market value of US$ 11.9 billion by 2033.
FMI has projected North America to be one of the most lucrative regions for Hypoventilation management market.
South Asia region is anticipated to grow fastest during the forecast period.
1. Executive Summary | Hypoventilation Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033
5.3.1. Chronic Obstructive Pulmonary Disease
5.3.2. Obesity Hypoventilation Syndrome (OHS)
5.3.3. Central Alveolar Hypoventilation
5.3.4. Neuromuscular Disorders
5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
6.3.1. Oxygen Therapy
6.3.2. Non-invasive Mechanical Ventilation
6.3.3. Drug Therapy
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End Users , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users , 2023 to 2033
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Home Care
7.4. Y-o-Y Growth Trend Analysis By End Users , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End Users , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MIDDLE EAST AND AFRICA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Disease Type
9.2.3. By Treatment
9.2.4. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Disease Type
9.3.3. By Treatment
9.3.4. By End Users
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Disease Type
10.2.3. By Treatment
10.2.4. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Disease Type
10.3.3. By Treatment
10.3.4. By End Users
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Disease Type
11.2.3. By Treatment
11.2.4. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Disease Type
11.3.3. By Treatment
11.3.4. By End Users
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Disease Type
12.2.3. By Treatment
12.2.4. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Disease Type
12.3.3. By Treatment
12.3.4. By End Users
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Disease Type
13.2.3. By Treatment
13.2.4. By End Users
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Disease Type
13.3.3. By Treatment
13.3.4. By End Users
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Disease Type
14.2.3. By Treatment
14.2.4. By End Users
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Disease Type
14.3.3. By Treatment
14.3.4. By End Users
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of Middle East and Africa
15.2.2. By Disease Type
15.2.3. By Treatment
15.2.4. By End Users
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Disease Type
15.3.3. By Treatment
15.3.4. By End Users
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Disease Type
16.1.2.2. By Treatment
16.1.2.3. By End Users
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Disease Type
16.2.2.2. By Treatment
16.2.2.3. By End Users
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Disease Type
16.3.2.2. By Treatment
16.3.2.3. By End Users
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Disease Type
16.4.2.2. By Treatment
16.4.2.3. By End Users
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Disease Type
16.5.2.2. By Treatment
16.5.2.3. By End Users
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Disease Type
16.6.2.2. By Treatment
16.6.2.3. By End Users
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Disease Type
16.7.2.2. By Treatment
16.7.2.3. By End Users
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Disease Type
16.8.2.2. By Treatment
16.8.2.3. By End Users
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Disease Type
16.9.2.2. By Treatment
16.9.2.3. By End Users
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Disease Type
16.10.2.2. By Treatment
16.10.2.3. By End Users
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Disease Type
16.11.2.2. By Treatment
16.11.2.3. By End Users
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Disease Type
16.12.2.2. By Treatment
16.12.2.3. By End Users
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Disease Type
16.13.2.2. By Treatment
16.13.2.3. By End Users
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Disease Type
16.14.2.2. By Treatment
16.14.2.3. By End Users
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Disease Type
16.15.2.2. By Treatment
16.15.2.3. By End Users
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Disease Type
16.16.2.2. By Treatment
16.16.2.3. By End Users
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Disease Type
16.17.2.2. By Treatment
16.17.2.3. By End Users
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Disease Type
16.18.2.2. By Treatment
16.18.2.3. By End Users
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Disease Type
16.19.2.2. By Treatment
16.19.2.3. By End Users
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Disease Type
16.20.2.2. By Treatment
16.20.2.3. By End Users
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Disease Type
16.21.2.2. By Treatment
16.21.2.3. By End Users
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Disease Type
17.3.3. By Treatment
17.3.4. By End Users
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Accord Healthcare Limited
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Avet Pharmaceuticals Inc
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Nostrum Laboratories Inc
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Lannett Co Inc
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Strides Pharma Science Limited
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. X Gen Pharmaceuticals Inc
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. ResMed
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Koninklijke Philips NV
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Hikma Pharmaceuticals
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Lincare Holdings
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Hypoventilation Management Market
